Sam Chun Dang Pharm. Co., Ltd
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-98.4% vs price
Base Case (Median)
-96.8% vs price
Bull Case (75th pct.)
-96.3% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-4050.21 | -101.5% | High (40%) |
| PE Comparable | $9726.74 | -96.3% | Medium (25%) |
| Graham Number | $10886.23 | -95.8% | Medium (40%) |
| EV/EBITDA | $8393.56 | -96.8% | Medium (20%) |
| Earnings Power Value | $4230.95 | -98.4% | Medium (50%) |
Based on 5 out of 8 methods, 000250.KQ appears overvalued at the current price of $261500.00. The base case fair value of $8393.56 implies 96.8% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.